Supriya lifescience share price

Supriya Lifescience Ltd is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (APIs). It focuses on products in various therapeutic segments, such as Antihistamine, Anti-Allergic, Vitamins, Anesthetics, Ant-Malarial and Anti-Asthmatics. It handles chemical reactions, such as Friedel Craft’s Acylation, Claisen Condensation, Grignard Reaction, Mannich Reaction, Ritter Reaction, Eschweiler Clark reaction, Hydrogenation, Chlorination, Bromination, Decyanation, Isocyanation, Ethoxylation, Nitration, Alkylation, Reduction, Oxidation, Etherification, Chlorosulphonation, Phosphorylation, Chiral resolution, Heterocyclic chemistry, Thermal ring expansion and Protection/Deprotection. Its manufacturing facilities include delineated areas for quality check; manufacturing areas with multiple clean rooms; engineering and maintenance; warehouse; materials and finished goods stores; in-house microbiological laboratory, and functional waste treatment plant.;

Supriya Lifescience Ltd is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (APIs). It focuses on products in various therapeutic segments, such as Antihistamine, Anti-Allergic, Vitamins, Anesthetics, Ant-Malarial and Anti-Asthmatics. It handles chemical reactions, such as Friedel Craft’s Acylation, Claisen Condensation, Grignard Reaction, Mannich Reac tion, Ritter Reaction, Eschweiler Clark reaction, Hydrogenation, Chlorination, Bromination, Decyanation, Isocyanation, Ethoxylation, Nitration, Alkylation, Reduction, Oxidation, Etherification, Chlorosulphonation, Phosphorylation, Chiral resolution, Heterocyclic chemistry, Thermal ring expansion and Protection/Deprotection. Its manufacturing facilities include delineated areas for quality check; manufacturing areas with multiple clean rooms; engineering and maintenance; warehouse; materials and finished goods stores; in-house microbiological laboratory, and functional waste treatment plant. • Revenue in INR (TTM) 4.61bn • Net income in INR 898.58m • Incorporated 2008 • Employees -- • Location Supriya Lifescience Ltd Sonawala Road Goregoan 207/208, Udyog Bhavan MUMBAI 400 063 India IND • Phone +91 2 240332727 • Fax +91 2 226860011 • Website Company Revenue (TTM) Net income (TTM) Market cap Employees Price/earnings (TTM) Price/book value (MRQ) Price/cash flow (TTM) Price/sales (TTM) EPS (excl. extraordinary items, TTM) EPS (incl. extraordinary items, TTM) Revenue per share (TTM) Bo...

• The company has shown a good profit growth of 56.7400200691836% for the Past 3 years. • The company has shown a good revenue growth of 24.0241182196778% for the Past 3 years. • The company has significantly decreased its debt by 48.835 Cr. • Company has been maintaining healthy ROE of 51.3069037544487% over the past 3 years. • Company has been maintaining healthy ROCE of 51.0458233152324% over the past 3 years. • Company is virtually debt free. • Company has a healthy Interest coverage ratio of 50.3675559790376. • The Company has been maintaining an effective average operating margins of 26.6235139204236% in the last 5 years. • The company has an efficient Cash Conversion Cycle of 16.4127706493742 days. • Company has a healthy liquidity position with current ratio of 4.99044122809657. • The company has a high promoter holding of 68.28%. Quarterly Result (All Figures in Cr.) PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Net Sales 181.27 101.36 112.17 105.14 142.27 Total Expenditure 106.05 70.11 60.63 91.1 87.23 Operating Profit 75.22 31.25 51.54 14.04 55.05 Other Income 3.86 2.36 2.61 2.56 1.96 Interest 1.02 0.58 23.76 1.01 0.71 Depreciation 2.58 2.89 2.97 2.95 3.01 Exceptional Items 0 0 0 0 0 Profit Before Tax 75.48 30.14 27.42 12.64 53.29 Tax 29.27 4.89 10.56 3.13 15.06 Profit After Tax 46.21 25.25 16.86 9.52 38.23 Adjusted EPS (Rs) 5.74 3.14 2.1 1.18 4.75 Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.) PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 M...

Supriya Lifescience shares made a bumper listing on stock exchanges today amid positive market sentiment. Shares of the active pharmaceuticals ingredients (API) manufacturer started trading at Rs 425 per share, 55.11% or Rs 151 apiece higher than the upper end of the price band of Rs 274 per share. The Rs 700 crore public issue of Supriya Lifescience was a mix of fresh issuance of equity shares and an offer for sale (OFS) by existing shareholders. The company is a manufacturer and supplier of APIs, with a focus on research and development. Supriya Lifescience had a market capitalization of Rs 3,420 crore on opening. The Rs 700 crore Supriya Lifescience IPO was subscribed 71.51 times earlier this month with Non-Institutional Investors (NII) bidding for their portion 161.22 times. The retail portion was subscribed 56 times and the QIB portion was bid for 31.83 times. Shares were offered in a fixed price band of Rs 265-274 per share. Post issue, promoter shareholding in the company will come down to 68.24% from 99.98% prior to the public issue. The public shareholding will therefore increase to 31.76% from 0.02% pre-IPO. “Supriya owns 38 APIs focused on diverse therapeutic segments along with being the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India. At the upper price band, it is valued at ~13.3x EV/EBITDA and ~17.8x P/E for FY21,” said analysts at ICICI Direct. The brokerage firm did not rate the IPO. Funds raised through the IPO will be u...

Supriya Lifescience Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Supriya Lifescience Ltd.: Share Price, Stock Analysis, Annual Report | Value Research https://www.valueresearchonline.com/stocks/290113/supriya-lifescience-ltd/ Get Supriya Lifescience Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house. Business Supriya Lifescience Ltd. engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. It offers active pharmaceutical ingredients, such as, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, and anti-malarial products, as well as vitamins, and xanthine derivatives. The company was founded in 1987 and is headquartered in Mumbai, India.